Real-World Effectiveness of Omalizumab in Chronic Urticaria: A Clinical Observational Study
International Archives of Allergy and Immunology · 2024 · 185 (7) · 718-728
DOI: 10.1159/000538011 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift International Archives of Allergy and Immunology, online erschienen am 21.03.2024. Verfasst von Fan Zhang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology and Venereology, Beijing Jishuitan Hospital, Capital Medical University, Beijing, China. Hauptthemen laut MEDLINE: Omalizumab, Chronic Urticaria, Anti-Allergic Agents. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Introduction
The purpose of this study was to assess the clinical effectiveness and safety profile of omalizumab as a therapeutic intervention for chronic urticaria (CU).
Methods
From March 1, 2023, to September 30, 2023, data on a cohort comprising 96 patients with CU, who underwent treatment with omalizumab at our medical institution’s allergy clinic, were systematically compiled. Subsequent to the administration of omalizumab, the therapeutic efficacy was assessed utilizing the 7-day urticaria activity score and the urticaria control test.
Results
Based on the statistical analysis, the mean duration of therapeutic intervention was 2.4 ± 1.3 months, with a corresponding mean cumulative dosage of 765 ± 450 mg. Of the subset of 42 patients with CU who were subjected to a follow-up period exceeding 3 months, it was observed that the treatment led to complete symptom remission, and no instances of recurrence were documented. Notably, there were statistically significant differences in the treatment duration and the cumulative dosage between patients who experienced co-morbid conditions and those who did not (p < 0.01, 95% CI: 0.280–1.326; p < 0.01, 95% CI: 0.597–2.997). Furthermore, there were significant differences in the treatment duration and cumulative dosage between patients in the combined allergic rhinitis group and those in the non-combined allergic rhinitis group (p < 0.01, 95% CI: 0.204–1.305; p = 0.01, 95% CI: 0.326–2.860).
Conclusion
Omalizumab demonstrates efficacy in the management of CU among Chinese patients by exerting effective symptom control and facilitating the regression of skin lesions. The assessment of its therapeutic efficacy typically requires a 12-week treatment period. Moreover, the co-occurrence of CU with other allergic disorders serves as a pertinent consideration for the adjustment of omalizumab dosing regimens.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatology and Venereology, Beijing Jishuitan Hospital, Capital Medical University, Beijing, China.
- Peking University School of Medicine, School of Clinical Medicine, Beijing, China.
Zitieren
APA
Zhang, F., Liao, J., Qian, Y., Niu, X., Wei, J., Li, M., Guo, D., & Zhu, P. (2024). Real-World Effectiveness of Omalizumab in Chronic Urticaria: A Clinical Observational Study. International Archives of Allergy and Immunology, 185(7), 718-728. https://doi.org/10.1159/000538011
Vancouver
Zhang F, Liao J, Qian Y, Niu X, Wei J, Li M, et al. Real-World Effectiveness of Omalizumab in Chronic Urticaria: A Clinical Observational Study. International Archives of Allergy and Immunology. 2024;185(7):718-728. doi:10.1159/000538011
BibTeX
@article{Zhang2024,
author = {Zhang, Fan and Liao, Jiashun and Qian, Yuan and Niu, Xinyu and Wei, Jia and Li, Man and Guo, Duyi and Zhu, Peiqiu},
title = {Real-World Effectiveness of Omalizumab in Chronic Urticaria: A Clinical Observational Study},
journal = {International Archives of Allergy and Immunology},
year = {2024},
volume = {185},
number = {7},
pages = {718--728},
doi = {10.1159/000538011}
}
EUVIMED